Obesity trials recruiting in Indiana

All Obesity trials nationally

Cities in Indiana

Recruiting trials in Indiana

• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
  NCT07639021 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
  NCT06717698 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Valparaiso
• A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
  NCT07253285 · Phase: Phase 3 · Ages: 8 Years to 18 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Hammond, Indianapolis
• A Sensory Strategy to Cut Sugary Beverages in African/American and Latine Adolescents
  NCT07223151 · Phase: Not applicable (e.g. observational or device study) · Ages: 12 Years to 18 Years · Sex: All (male and female) · Indiana: Bloomington, Indianapolis, West Lafayette
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
  NCT06897475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Indiana: Brownsburg
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Evansville, Indianapolis, Valparaiso
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
  NCT07743463 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Evansville, Indianapolis, Valparaiso
• A Study of Pitolisant in Patients With Prader-Willi Syndrome
  NCT06366464 · Phase: Phase 3 · Ages: 6 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
  NCT06439277 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: New Albany
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Indianapolis, Plainfield
• A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
  NCT07595549 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Evansville
• AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
  NCT07503210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
  NCT07339423 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• Effects of Body Composition on Vascular Health in Females With a Healthy Body Weight
  NCT06818500 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 50 Years · Sex: Female · Indiana: Muncie
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
  NCT07353931 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Evansville
• Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
  NCT07497880 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Indiana: South Bend
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female) · Indiana: Munster, Valparaiso
• Fibrosis Lessens After Metabolic Surgery
  NCT06374875 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Indiana: Indianapolis
• Gut, Immune, and Vascular Health in Metabolically Healthy Obesity
  NCT07559227 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 55 Years · Sex: All (male and female) · Indiana: Muncie
• Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes
  NCT07095426 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 55 Years · Sex: All (male and female) · Indiana: Muncie
• Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
  NCT05124808 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 45 Years · Sex: Female · Indiana: Indianapolis
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Indiana: Elkhart, Indianapolis, Munster, Richmond
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
  NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Indiana: Indianapolis, New Albany
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Indiana: Indianapolis, New Albany
• The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
  NCT05414409 · Phase: Phase 2 · Ages: 11 Years to 18 Years · Sex: All (male and female) · Indiana: Indianapolis